EP Patent

EP4292588A2 — Administration of deuterated cftr potentiators

Assigned to Vertex Pharmaceuticals Europe Ltd · Expires 2023-12-20 · 2y expired

What this patent protects

Disclosed is a method of treating in a subject of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator The method comprises administering to the subject an amount in the range of about 50 mg to about 200 mg once a day of Compound (I) …

USPTO Abstract

Disclosed is a method of treating in a subject of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator The method comprises administering to the subject an amount in the range of about 50 mg to about 200 mg once a day of Compound (I) or (II): or or pharmaceutically acceptable salts thereof. This invention also provides compositions comprising Compound (I) or (II) and the use of such compositions in methods.

Drugs covered by this patent

Patent Metadata

Patent number
EP4292588A2
Jurisdiction
EP
Classification
—
Expires
2023-12-20
Drug substance claim
No
Drug product claim
No
Assignee
Vertex Pharmaceuticals Europe Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.